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Abstract: Herein, we report the third generation of fluo-
rescent probes (arylphosphonic acids) to target calcifica-
tions, particularly hydroxyapatite (HAP). In this study, we
use highly conjugated porphyrin-based arylphosphonic
acids and their diesters, namely 5,10,15,20-tetrakis[m-(di-
ethoxyphosphoryl)phenyl]porphyrin (m-H8TPPA-OEt8) and
5,10,15,20-tetrakis [m-phenylphosphonic acid]porphyrin
(m-H8TPPA), in comparison with their positional isomers
5,10,15,20-tetrakis[p-(diisopropoxyphosphoryl)phenyl]por-
phyrin (p-H8TPPA-iPr8) and 5,10,15,20-tetrakis [p-phenyl-
phosphonic acid]porphyrin (p-H8TPPA), which have phos-
phonic acid units bonded to sp2 carbon atoms of the fluo-
rescent core. The conjugation of the fluorescent core is
thus extended to the (HAP) through sp2-bonded @PO3H2
units, which generates increased fluorescence upon HAP
binding. The resulting fluorescent probes are highly sensi-
tive towards the HAP in rat bone sections. The designed
probes are readily taken up by cells. Due to the lower re-
ported toxicity of (p-H8TPPA), these probes could find ap-
plications in monitoring bone resorption or adsorption, or
imaging vascular or soft tissue calcifications for breast
cancer diagnosis etc.
Dysregulation of calcium and phosphate homeostasis often
leads to the pathological deposition of minerals, such as calci-
um carbonate (CC), calcium oxalate (CO), calcium phosphate
(CP), calcium pyrophosphate (CPP), and hydroxyapatite (HAP)
in many soft tissues,[1, 2] such as those in the brain,[3] eye,[4]
kidney[5] and skin.[2, 6] The pathological deposition of these min-
erals causes these tissues to become inflexible or even brittle,
which can lead to uncontrolled access of extracellular materials
or prevent the passive diffusion of molecules between cells
and their environment, likely leading to cell death.[6] In addi-
tion, minerals like HAP can facilitate the retention of molecules
by providing a binding surface for the pathological accumula-
tion of molecules.[7a] Detecting and monitoring increased calci-
fication can be a valuable early indication of breast cancer.[8]
Conversely, monitoring the decrease in mineralization can be
useful for assessing osteoporosis.[9] In addition, evidence is
emerging that HAP deposition may play a role in the develop-
ment and progression of age-related macular degeneration in
the retina and neurodegeneration in the brain.[7] Therefore,
monitoring calcification in health and disease is critical for di-
agnosis, monitoring progression and treatment.
There are several methods used to monitor calcification,
some applicable in vivo while others only work in vitro.[10, 11] A
number of radiological techniques have the potential to detect
calcification using radiography,[12, 13] fluoroscopy,[13] convention-
al computed tomography (CT),[14] electron-beam tomography
(EBT),[15, 16] multi-detector CT,[17, 18] intravascular ultrasound,[19, 20]
magnetic resonance imaging (MRI),[21] and transthoracic and
transesophageal echocardiography.[22] However, most current
methods cannot resolve smaller than millimeter sized mineral-
ization and are usually invasive, costly and not well tolerat-
ed.[23] In vitro, the resolution can be significantly increased: The
classic Von Kossa histochemical method relies on silver precipi-
tation at sites of phosphate deposition,[24] while Alizarin Red S,
a colorimetric label, is widely used to detect calcium deposi-
tion.[25] In combination these are effective, inexpensive and
widely used methods to detect calcium phosphate mineraliza-
tion in fixed cells in culture or postmortem tissue sections, but
they are not very sensitive and subcellular resolution is limited.
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Fluorescent probes broadly offer better sensitivity than colori-
metric ones, but existing stains such as Alizarin Red S, Xylenol
Orange, or uranium have clear drawbacks such as modest se-
lectivity among mineral phases, pH dependence, overlap of
their fluorescence with tissue autofluorescence. Frangioni and
Kovar’s research groups developed the second generation
fluorescent probes coupling HAP-binding moieties such as bis-
phosphonate or tetracycline with red and near-infrared penta-
or hepta-methine cyanine fluorescent moieties; the longer
wavelength excitation and emission of these fluorophores sub-
stantially reduces scattering and background fluorescence.[26–28]
These probes were sensitive, selective, and usable in vivo in
animal models, but are costly and by comparison with other
probes that exhibit significant or unique changes in fluores-
cence when binding to particular targets such as DNSA
(dansylamide) with carbonic anhydrase,[29] the triphenyl meth-
ane dye Auramine O with LADH (horse liver alcohol dehydro-
genase) with,[30] or ethidium bromide with DNA,[31] their fluo-
rescence is insensitive to whether they have bound to the (cal-
cified) target or nonspecifically to something else. To address
this latter issue, we sought to develop the third generation of
fluorescent probes of calcification bearing phosphonic acid
metal binding units which are bonded to one of the sp2
carbon atoms of the fluorescent cores, with the goal of differ-
entially perturbing the fluorescence of the probe when bound
to calcified substrates, and thereby providing additional infor-
mation. The use of such fluorophores would be important with
respect to generating synergic interactions between the fluo-
rescent core and the d orbitals of the target divalent metal
ions.
In this sense, the phosphonic acid metal binding group has
recently attracted significant attention in diverse scientific
fields ranging from material science to medicine.[32, 33] Our initial
toxicity studies with aromatic phosphonic acids and phospho-
nate metal-organic solids were promising for their in vivo ap-
plications inasmuch as p-H8TPPA exhibited no toxicity for an
intestinal cell line at high concentrations.[34, 35] One of the unex-
plored properties of phosphonic acid metal binding groups is
their potential role in imaging metal deposits in living systems.
Our and Demadis’ recent work, and Martell’s early work from
the 1970s all indicate that phosphonates exhibit high affinity
towards alkali and alkaline earth metal ions, as well as divalent
transition-metal ions.[35–39] In addition, the pKa2 of phenylphos-
phonic acid (PhPO3H2) is 7.44, giving PhPO3
2@ a @2 charge
under physiological pH.[40] Therefore, the use of phosphonic
acid metal-binding unit(s) to target biologically significant diva-
lent metal ions offers highly sensitive and pH-independent
metal probes working near physiological pH. Bisphosphonates
have been previously attached to cyanine (OsteosenseS) and
fluorescein moieties with long aliphatic hydrocarbon side
chains to label target calcification with green or near infrared
fluorescence.[39, 41] The presence of sp3 bonds in the aliphatic
linker chain in these examples between the phosphonic acid
and the fluorescent core in these examples merely used bis-
phosphonates as recognition moieties and minimized any elec-
tronic interactions between the fluorescent core and the phos-
phonic acid metal binding unit. Therefore, such fluorescent
labels provide little if any change in fluorescence intensity
upon HAP binding.[39, 41–43] By comparison, the direct conjuga-
tion of phosphonic acid metal binding group with an sp2
carbon atom of the fluorescent core extends the conjugation
of the fluorescent core up to the coordinated metal ion. Thus,
it offers the prospect of the metal-ion binding the phospho-
nate and affecting the fluorescence in useful ways. For in-
stance, such binding and recognition of a metal ion might
cause useful changes in fluorescence that might help discrimi-
nate metal-bound fluorophores from unbound or non-specifi-
cally bound fluorophores. Such fluorescent phosphonates con-
taining direct sp2 conjugation with the fluorescent core have
not been reported in the literature, perhaps due to synthetic
difficulties and the high energy requirement to form P@C
bonds. Our recent research efforts with arylphosphonic acid
synthesis have generated novel strategies to introduce phos-
phonic acid around aromatic scaffolds, by Suzuki cross cou-
pling or the d-catalyzed Arbuzov reaction.[44–47]
For this study, as seen in Scheme 1, we have synthesized 4
fluorescent probes. Two of them incorporate phenylphosphon-
ic acid as the HAP binding unit with highly conjugated porphy-
rin cores, namely 5,10,15,20-tetrakis[p-phenylphosphonic acid]-
porphyrin (p-H8TPPA) and 5,10,15,20-tetrakis[m-phenylphos-
phonic acid]porphyrin (m-H8TPPA) (Figure 1; please see the
Supporting Information for synthesis details). p-H8TPPA has
four para-positioned PPA units promoting direct conjugation
between the HAP and the fluorescent core. On the other hand,
m-H8TPPA has four meta-positioned PPA units creating a more
protective environment between the fluorescent porphyrin
core and the HAP. We then explored their potential for binding
hydroxyapatite. As a control group we used the isopropyldiest-
er and ethyldiester analogues of p-H8TPPA and m-H8TPPA,
namely p-H8TPPA-iPr8 and m-H8TPPA-OEt8 (see the Supporting
Scheme 1. The fluorescent probes used in this study: A) 5,10,15,20-Tetra-
kis[p-(diisopropoxyphosphoryl)phenyl]porphyrin (p-H8TPPA-iPr8).
B) 5,10,15,20-Tetrakis [p-phenylphosphonic acid]porphyrin (p-H8TPPA).
C) 5,10,15,20-Tetrakis[m-(diethoxyphosphoryl)phenyl]porphyrin (m-H8TPPA-
OEt8). D) 5,10,15,20-Tetrakis [m-phenylphosphonic acid]porphyrin (m-
H8TPPA).




Information for detailed synthesis). A previous synthesis of p-
H8TPPA relied on the Ni-catalyzed Arbuzov reaction.
[48] There-
fore, p-H8TPPA that is synthesized using this route usually has
Ni bound to the nitrogens in the porphyrin core. In this study,
we have used an alternative method using Pd-catalyzed Arbu-
zov reaction to obtain metal free p-H8TPPA. (please see the
Supporting Information for synthesis details, NMR, FTIR spec-
tra, and the crystallographic tables).
To probe their HAP binding properties in a biological matrix,
we have used cross sectioned mouse ribs as an example for
naturally occurring HAP. The sections were incubated with p-
H8TPPA, m-H8TPPA and p-H8TPPA-iPr8 at concentrations rang-
ing from 0.01 to 1.0 mg mL@1 in HEPES buffer for varying times
at room temperature, then imaged by fluorescence microscopy
(details below in the figure legends), to assess HAP binding ca-
pability. Ribs incubated with 1 mg mL@1 p-H8TPPA showed a
greater fluorescence intensity than both 0.1 mg mL@1 and
0.01 mg mL@1 (Figure S17 A–C, respectively), whilst still showing
clear fluorescence signal at the lowest concentration of
0.1 mg mL@1 used here.
This indicates that the dye binding to HAP is concentration
dependent. When the mouse ribs were incubated with
1 mg mL@1 p-H8TPPA in HEPES for differing times from 120 to
10 mins (Figure S18 A–E), there was a clear decrease in fluores-
cence intensity but even the 10 min short incubation yielded
an appreciable fluorescence compared to the negative control
(Figure S18 E compared to Figure S18 F). When ribs were incu-
bated with p-H8TPPA diluted to 1 mg mL
@1 in different buffers,
there was no clear difference between the fluorescence inten-
sity of HEPES, PBS, TBS (Figure S19 A–C, respectively). However,
when p-H8TPPA was diluted in dH2O (Figure S19 D), there was
no fluorescent signal observed. Sections were re-imaged at
several time points after the original microscopy sessions to
observe the stability of labeling. There was a noticeable de-
crease in fluorescence intensity in all of the solvents although
signal diminished faster in HEPES buffer than in PBS or TBS
(Figure S20). At the two week time point there was still a weak
fluorescent signal observed for p-H8TPPA diluted in PBS, but
not for the other buffers (Figure S20 N compared to Fig-
ure S20 M, O and P). No signal was associated with incubating
the ribs with the solvents as a negative control (Figure S20 Q-T)
The phosphonic acid moieties in m-H8TPPA are more pro-
tected compared to the para-positioned p-H8TPPA. When
mouse ribs were incubated with different concentrations of m-
H8TPPA, (1 to 0.01 mg mL
@1 in HEPES buffer) we found little to
no difference in the fluorescence intensities (Figure S21 A–C,
respectively). When the mouse ribs were incubated with
1 mg mL@1 m-H8TPPA in HEPES for differing times, 10 to 120
mins, there were no appreciable difference in fluorescence in-
tensities at the different incubation times (Figure S22 A–E, re-
spectively) while the fluorescent intensities were clearly distin-
guishable from HEPES alone (Figure S22 F). Imaging of the sec-
tions were repeated two weeks following the original micros-
copy and we found no noticeable decrease in fluorescence in-
tensity between ribs incubated with 1 mg mL@1 m-H8TPPA in
HEPES buffer and imaged on the day of staining compared
with images taken 4, 7 and 14 days later (Figure 1 F–I, respec-
tively). This is a noticeable difference compared to p-H8TTPA,
with a less protected structure, where there is a loss of fluores-
cent signal with increasing time after initial staining (Fig-
ure 1 A–D, respectively). This could be associated with the
more protected HAP phosphonic acid interaction in the meta
position limiting the interactions with the surrounding mole-
cules buffers etc. Again, no signal was associated with incubat-
ing the ribs with HEPES only as a negative control (Figure 1 E
and I, respectively).
As seen in Figure 2, the absorbance peak (Figure 2 A) of p-
H8TTPA in PBS, TBS and HEPES with the addition of HAP corre-
Figure 1. Mouse ribs incubated with either p-H8TPPA (lex/em 595/613 nm; ex-
posure time @200 ms) or m-H8TPPA (lex/em 578/603 nm; exposure time
@100 ms) diluted to 1 mg mL@1 in HEPES (A–E or F–J, respectively) and coun-
ter-stained with DAPI (lex/em 359/461 nm; exposure time: @200 or 100 ms,
respectively). Images were captured on the day of staining (A and F), as well
as after 4 days (B and G), 7 days (C and H), and 14 days (D and I). A negative
control of mouse ribs incubated with each buffer alone is also included (E
and J, respectively). Scale bar = 100 mm.




sponds with the absorbance of the dye in d-DMSO (Fig-
ure S16). There is a noticeable shift in the absorbance peak
maximum when diluted in d H2O, from 415 nm to 435 nm,
which suggests a shift in the fluorescent properties of the dye
due to protonation. This is also reflected in the maximal peak
of the fluorescence intensity (Figure 2 B), with a shift from lem
646–648 nm for PBS, TBS and HEPES to lem 675 nm when dilut-
ed in dH2O. The fluorescence intensity of p-H8TPPA is also sub-
stantially increased by 1.8-, 2.0-, 2.0-, and 1.6-fold upon HAP
binding of the fluorescent probe p-H8TPPA in PBS, TBS, HEPES
and d H2O, respectively (Figure 2 B, solid vs. dashed lines). Pre-
viously reported bisphosphonate fluorophores had sp3 aliphat-
ic carbons between the fluorescent core and HAP binding,
therefore, such systems merely functioned as fluorescent labels
with no change in emission due to HAP binding since they
lacked synergistic interaction between the HAP and the fluo-
rescent core. Phosphonic acids that have direct sp2 bonds to
the fluorescent core could extend the conjugation of the fluo-
rescent core to the HAP and thereby could initiate changes in
the ground and excited states resulting in quenching or en-
hancing the fluorescence emission. As seen in Figure 2 (B),
upon binding of HAP, p-H8TPPA produces increased fluores-
cence supporting this hypothesis ; p-H8TPPA is thus the first ex-
ample of a single sp2 bonded phosphonic acid unit targeting
HAP in the literature.
Comparable experiments with mouse rib sections were con-
ducted using the isopropyldiester forms p-H8TPPA-iPr8 and m-
H8TPPA-OEt8 (See Scheme 1 a and 1 c) as stains. We found a
complete lack of HAP-associated staining with these com-
pounds suggesting that the interaction of phosphonates with
HAP was reduced by the isopropylester groups on the phos-
phonates, preventing binding and interaction of the fluores-
cent porphyrin core with the HAP. We also noted that the pres-
ence of hydrophobic isopropyl groups dramatically reduced
their solubilities in the aqueous.
Aiming to use phenylphosphonic acid functionalized por-
phyrins in in vivo applications, the negative charge on the de-
protonated phosphonate might be a handicap by limiting cell
permeability. Optional demasking of phosphonate esters in
metabolic surroundings might occur, recreating the metal
binding PhPO3
2@. This possibility led us to examine p-H8TPPA
and p-H8TPPA-iPr8 suitability for in vivo cellular experiments
by testing their permeability on proliferating human THP-1
monocytes. The cells were probed with either p-H8TPPA or p-
H8TPPA-iPr8 in a HEPES-based buffer containing 0.3 % bovine
serum albumin. Albumin binds a wide variety of hydrophobic
ligands under physiological conditions, so we assumed an im-
proved solubility/accessibility for the isopropyl diester mole-
cule for cellular uptake. In addition, albumin is a regular com-
ponent of culture media.
As seen in Figure 3, the fluorescence spectra of p-H8TPPA-
loaded THP-1 cells very much resembles the characteristics of
the sensor diluted in HEPES-buffer (see Figure 1 A, F). Thus,
beyond the low toxicity p-H8TPPA provides two more positives
-cell permeability and cellular retention- desirable for imaging
applications. p-H8TPPA-iPr8 was much less efficient in labeling
the THP-1 cells (see Figure S23). We hypothesize that the phe-
nylphosphonic acid porphyrins, being somewhat amphipathic,
were able to penetrate the cell membrane, whereas the more
nonpolar esters were not as efficient.
In conclusion, herein, we have reported next-generation
fluorescent probes to target calcifications, namely p-H8TPPA,
m-H8TPPA, p-H8TPPA-iPr8, and m-H8TPPA-OEt8, in which the
phosphonic acid metal binding unit(s) are exclusively bonded
to sp2 carbon atoms of the fluorescent core. sp2 bonding of
the metal binding unit to the fluorescent core further extend-
ed the conjugation of the fluorescent core to the HAP, leading
to significant increase in fluorescence upon HAP binding. We
further used these fluorescent probes to target the HAP in
mouse ribs and observed their interaction with human cells.
Both m-H8TPPA and m-H8TPPA have shown HAP specific bind-
ing in rat bone sections. The more protected metal binding
nature of the m-H8TPPA resulted in longer fluorescence period
compared to its positional isomer p-H8TPPA. As a control, we
have also synthesized phosphonatediesters of the synthesized
fluorescent probes, which showed no HAP binding. p-H8TPPA
can travel through the cellular membrane, whereas the pres-
Figure 2. The absorbance (A) and fluorescence (B) spectra of 0.01 mg mL@1 p-H8TPPA in the presence (dashed lines) and absence (solid lines) of HAP. The dye
was diluted to 0.01 mg mL@1 in PBS (pH 7.4, green), TBS (pH 7.4, orange), HEPES (pH 7.4, purple) and d H2O with absorbance and fluorescence spectra obtained
using the Flexstation 3 microplate reader.
Figure 3. Fluorescence spectra of THP-1 monocytes cells incubated with p-
H8TPPA.




ence of bulky and hydrophobic isopropyl groups in p-H8TPPA-
iPr8 hindered their passage through the cellular membrane.
This is the first study utilizing sp2-bonded phosphonic acids
with the fluorescent cores to target HAP mineralizations. We
have shown that compact fluorescent probes with phosphonic
acid metal binding group(s) may be used to monitor microcal-
cifications and calcifications. In addition, their easy acceptance
into the cellular matrix indicate that they could be used to
target organelle-specific calcifications such as mitochondrial
calcifications. The reported low toxicity of p-H8TPPA and the
new synthetic methods indicate that they can be used in tar-
geting wide range of calcifications in vivo. We are currently de-
veloping our library to target organelle specific calcifications.
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[47] A. Bulut, Y. Zorlu, M. Wçrle, A. Çetinkaya, H. Kurt, B. Tam, A. :zger Ya-
zaydin, J. Beckmann, G. Yecesan, ChemistrySelect 2017, 2, 7050 – 7053.
[48] T. Rhauderwiek, H. Zhao, P. Hirschle, M. Dçblinger, B. Bueken, H. Re-
insch, D. De Vos, S. Wuttke, U. Kolb, N. Stock, Chem. Sci. 2018, 9, 5467 –
5478.
Manuscript received: April 3, 2020
Accepted manuscript online: April 15, 2020
Version of record online: July 28, 2020
Chem. Eur. J. 2020, 26, 11129 – 11134 www.chemeurj.org T 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim11134
Chemistry—A European Journal
Communication
doi.org/10.1002/chem.202001613
